Peter Young


Pharma & Biotech: Financial Pulse-Check, Outlook

A review of market performance and trends in 2018 and first quarter of 2019 for the life sciences industry.

CFIUS Reform’s Impact on Biopharma

What the new rules mean for Chinese-related investments and acquisitions in the US.

Pharma and Biotech Markets: Challenges and Opportunities

With the soaring valuations of companies in the public and M&A markets now seemingly a distant memory, the challenge for pharma and biotech business will be choosing just the right overall mix of M&A, licensing, and partnering.

Pharma M&A Market: Latest Challenges and Opportunities

For ethical pharma companies, there continues to be a wide variety of tools to acquire revenues and pipeline drugs, but the valuations are challenging, writes Peter Young.